Table 3

Impact of HSV-2 seropositivity on HIV disease progressiona
Study Population N HSV-2 Ascertainment Results
Outcome HSV2 positive HSV2 negative Difference Effectb
Barnabas 2011 HIV seroconverters, Americas 87 Serology: Western Blot Initiation of HAART NR NR aHR = 1.3c, (95% CI = 0.5, 3.2)
Crum-Cianflone 2006 USA 367 Serology: Focus Time from HIV diagnosis to initiation of any ARTd 18 months 9 months p = 0.10
(range = 1,156) (range = 1,96)
271 Proportion with CD4≤350 or 18% at 1 year of follow-upe 62/144 = 43% 66/127 = 52% OR = 0.70, p = 0.15
221 Proportion with CD4≤350 or 18% at 3 years of follow-upe 84/118 = 71% 75/103 = 73% OR = 0.92, p = 0.88
Roxby 2011 Postpartum women, Kenya 296 Serology: Focus CD4≤200 50/254 = 20% 7/42 = 17% aHR = 1.16f, (95% CI = 0.52,2.56), p = 0.72
First OI 43/254 = 17% 2/42 = 5% aHR = 3.83f, (95% CI = 0.93,15.83), p = 0.06 Faster?
Death 17/254 = 7% 2/42 = 5% aHR = 1.33f, (95% CI = 0.32,6.05), p = 0.66
Suligoi 2001 Italy 380 Serology: Pockit AIDS NR NR HR = 1.68, (95% CI = 1.19,2.37), Adjustedg HR = 1.13, (95% CI = 0.76, 1.70) Faster?

aCI = confidence interval, HAART = highly active antiretroviral therapy, HR = hazard ratio, NR = not reported, OI = Opportunistic infection, OR = odds ratio.

bArrows show directions of association with HSV-2; ‘?’ denotes borderline statistical significance or clinically significant differences not meeting statistical significance.

cAdjusted for adenovirus 5 immunity, region, circumcision status, age, race, HLA group, trial intervention assignment (vaccine / placebo).

dIncludes any ART (monotherapy, non-HAART combination therapy and HAART).

eDefined as CD4 count <350 cells/mm3 or 18%.

fAdjusted for baseline CD4 count.

gAdjusted for age at HIV seroconversion, exposure category, sex.

Tan et al.

Tan et al. BMC Infectious Diseases 2013 13:502   doi:10.1186/1471-2334-13-502

Open Data